Auro Laboratories Ltd

Auro Laboratories has a debt-to-equity ratio of 0.63, indicating a moderate level of leverage relative to its equity base. The company's liquidity position is assessed as medium, with a current ratio of 1.29, suggesting it can cover its short-term obligations but with limited buffer. The company's cash and equivalents amount to INR 9.92 million, which is significantly lower than its long-term debt of INR 262.44 million, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, Auro Laboratories reports a return on equity (ROE) of 5.68% and a return on assets (ROA) of 2.78%. These figures are below the industry median for ROE and ROA, which are typically higher for pharmaceutical firms with strong R&D pipelines and market penetration. The company's net income of INR 23.82 million is derived from a revenue of INR 120.63 million, yielding a net margin of 19.75%. This margin is in line with the industry average, but the company's operating margin of 17.64% is slightly below the median for its sector.

Auro Laboratories' revenue is primarily concentrated in the United States and India, with the U.S. market being a key driver of its business. The company's exposure to these regions is significant, and any regulatory or market shifts in these jurisdictions could impact its financial performance. The company does not disclose detailed segment data, but its operations are largely focused on the pharmaceuticals business.

The company's growth trajectory is modest, with no specific revenue growth projections provided in the outlook. However, based on historical revenue data, the company has shown a stable performance. The capital expenditure of INR -356.40 million indicates a net outflow, which may be attributed to investments in infrastructure or R&D. The company's outlook for the current and next fiscal years is neutral, with no significant directional changes expected in revenue or profitability.

The risk assessment for Auro Laboratories highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in maintaining liquidity. However, the dilution risk is low, as the company has not issued additional shares recently, and there is no indication of imminent share dilution. The valuation adjustments applied to the company's price-to-earnings and price-to-book ratios reflect a conservative approach to its valuation.

Recent events and filings do not indicate any material changes in the company's operations or financial strategy. The company has not disclosed any significant new product launches or strategic partnerships in the latest filings. The absence of recent events suggests a stable but uneventful period for the company.

Cash conversion ratio of 7.89 is best-in-class, significantly outperforming the cohort median of 0.95.

Free cash flow improved by 22.0% year-over-year, signaling a positive trend in cash generation capabilities.

The company carries a high credit risk flag, suggesting potential difficulties in meeting financial obligations.

Debt-to-equity ratio of 0.63 places the company in the bottom quartile compared to peers.

Revenue CAGR of -22.7% over four years indicates a persistent long-term decline in business scale.